HomeCompareGMPUF vs ABBV

GMPUF vs ABBV: Dividend Comparison 2026

GMPUF yields 3.25% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GMPUF wins by $621.73M in total portfolio value· pulled ahead in Year 2
10 years
GMPUF
GMPUF
● Live price
3.25%
Share price
$3.38
Annual div
$0.11
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$621.83M
Annual income
$587,174,931.56
Full GMPUF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — GMPUF vs ABBV

📍 GMPUF pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGMPUFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GMPUF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GMPUF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GMPUF
Annual income on $10K today (after 15% tax)
$276.63/yr
After 10yr DRIP, annual income (after tax)
$499,098,691.83/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, GMPUF beats the other by $499,077,635.82/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GMPUF + ABBV for your $10,000?

GMPUF: 50%ABBV: 50%
100% ABBV50/50100% GMPUF
Portfolio after 10yr
$310.97M
Annual income
$293,599,851.66/yr
Blended yield
94.41%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

GMPUF
No analyst data
Altman Z
1.3
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GMPUF buys
0
ABBV buys
0
No recent congressional trades found for GMPUF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGMPUFABBV
Forward yield3.25%3.06%
Annual dividend / share$0.11$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$621.83M$102.3K
Annual income after 10y$587,174,931.56$24,771.77
Total dividends collected$619.30M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: GMPUF vs ABBV ($10,000, DRIP)

YearGMPUF PortfolioGMPUF Income/yrABBV PortfolioABBV Income/yrGap
1$11,351$650.89$11,550$430.00$199.00ABBV
2← crossover$13,526$1,380.96$13,472$627.96+$54.00GMPUF
3$17,549$3,075.96$15,906$926.08+$1.6KGMPUF
4$26,237$7,459.38$19,071$1,382.55+$7.2KGMPUF
5$48,919$20,845.19$23,302$2,095.81+$25.6KGMPUF
6$124,989$72,646.23$29,150$3,237.93+$95.8KGMPUF
7$480,680$346,941.62$37,536$5,121.41+$443.1KGMPUF
8$3,008,267$2,493,938.79$50,079$8,338.38+$2.96MGMPUF
9$32,392,582$29,173,736.42$69,753$14,065.80+$32.32MGMPUF
10$621,834,994$587,174,931.56$102,337$24,771.77+$621.73MGMPUF

GMPUF vs ABBV: Complete Analysis 2026

GMPUFStock

Gestamp Automoción, S.A. designs, develops, manufactures, and sells metal automotive components in Europe, North America, South America, and Asia. The company offers Body-in-White products, such as bonnets, roofs, doors, and mudguards, as well as other surface and assembly parts; and structural and crash-related elements that include floors, pillars, rails, and wheel arches. It also provides chassis parts, such as systems; frames and related parts comprising front and rear axles and couplings; control arms; and integrated couplings. In addition, the company offers mechanism parts, including hinges, door checks, electrical systems, and powered systems, as well as driver controls. It provides its products to manufacturers of light vehicles. The company was incorporated in 1997 and is headquartered in Madrid, Spain. Gestamp Automoción, S.A. is a subsidiary of Gestamp 2020, S.L.

Full GMPUF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this GMPUF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GMPUF vs SCHDGMPUF vs JEPIGMPUF vs OGMPUF vs KOGMPUF vs MAINGMPUF vs JNJGMPUF vs MRKGMPUF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.